Positive clinical data presentations at the Transcatheter Cardiovascular Therapeutics conference provided a primary bullish catalyst for Abbott Laboratories. The company announced encouraging one-year clinical outcomes from its VERITAS study evaluating the Amulet 360 Left Atrial Appendage Occluder, demonstrating high occlusion success and low complication rates in stroke prevention for atrial fibrillation patients. Simultaneously, Abbott highlighted successful results from its Tectonic study evaluating the SonicForce Coronary Intravascular Lithotripsy system for treating calcified coronary arteries. The dual readout reinforced investor confidence in the growth trajectory of the high-margin cardiovascular equipment portfolio.

The…